摘要
可溶性双胰岛素制剂德谷门冬双胰岛素制剂(IDegAsp)含70%德谷胰岛素和30%门冬胰岛素,两种组分在制剂中独立存在,皮下注射后各自发挥作用。为帮助临床更加合理及规范地应用IDegAsp,专家多次讨论形成了此版《德谷门冬双胰岛素临床应用专家指导意见》,对IDegAsp的作用机制、药代药动学特点进行阐述,并给出临床应用建议。IDegAsp可每日1次或每日2次注射,兼顾空腹血糖和餐后血糖控制。临床证据支持在多种临床场景下使用IDegAsp,并可用于胰岛素的起始或强化治疗。建议将IDegAsp作为口服药失效起始胰岛素治疗或需要胰岛素强化治疗患者的选择之一。
作者
朱大龙
赵维纲
匡洪宇
陆菊明
杨文英
郭立新
洪天配
母义明
纪立农
彭永德
王卫庆
姬秋和
陈丽
余学锋
时立新
冉兴无
李延兵
Zhu Dalong;Zhao Weigang;Kuang Hongyu;Lu Juming;Yang Wenying;Guo Lixin;Hong Tianpei;Mu Yiming;Ji Linong;Peng Yongde;Wang Weiqing;Ji Qiuhe;Chen Li;Yu Xuefeng;Shi Lixin;Ran Xingwu;Li Yanbing(Department of Endocrinology,Drum Tower Hospital Affiliated to Nanjing University Medical School,Nanjing 210008,China;Department of Endocrinology,Chinese Academy of Medical Science,Peking Union Medical College,Beijing 100730,China;Department of Endocrinology,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Endocrinology,the First Medical Center of PLA General Hospital,Beijing 100853,China;Department of Endocrinology,China Japan Friendship Hospital,Beijing 100029,China;Department of Endocrinology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Endocrinology,Peking University Third Hospital,Beijing 100191,China;Department of Endocrinology,Peking University,People′s Hospital,Beijing 100044,China;Department of Endocrinology and Metabolism,Shanghai First People′s Hospital,Shanghai Jiao Tong University,Shanghai 200080,China;Department of Endocrine and Metabolic Diseases,Shanghai Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200025,China;Department of Endocrinology and Metabolism,Xijing Hospital,Air Force Military Medical University,Xi′an 710032,China;Department of Endocrinology,Qilu Hospital,Shandong University,Institute of Endocrine and Metabolic Diseases of Shandong University,Key Laboratory of Endocrine and Metabolic Diseases,Shandong Province Medicine&Health,Jinan Clinical Research Center for Endocrine and Metabolic Diseases,Jinan 250012,China;Department of Endocrinology,Tongji Hospital,Tongji Medical College of Huazhong University of Science and Technology,Wuhan 430030,China;Department of Endocrinology and Metabolism,Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China;Department of Endocrinology and Metabolism,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Endocrinology,the First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China)
出处
《中华糖尿病杂志》
CAS
CSCD
北大核心
2021年第7期695-701,共7页
CHINESE JOURNAL OF DIABETES MELLITUS
